AP

Biogen tumbles after Medicare lays out Aduhelm coverage plan

Jan 12, 2022, 7:03 AM | Updated: 10:08 pm

Shares of Biogen slid Wednesday, a day after federal regulators slapped coverage limitations on the drugmaker’s new Alzheimer’s disease treatment.

The Centers for Medicare and Medicaid Services said Tuesday after markets closed that patients taking Biogen’s Aduhelm will have to also participate in clinical trials to assess the drug’s effectiveness in order for Medicare to cover the cost.

That’s an important caveat because Medicare is expected to cover most of the patients who opt for Aduhelm, and the drug can cost as much as $28,000 annually, not counting expenses for brain scans and other care patients will need while taking it.

Biogen had cut that cost down from more than $50,000 annually last month after taking months of criticism over the expense.

The initial Medicare coverage decision will significantly limit access to Aduhelm, said Mizuho Securities USA analyst Salim Syed. He had previously estimated around $3.5 billion to $4 billion in peak annual sales for the drug.

But he said Wednesday he now assumes less than $100 million.

Medicare’s national coverage determination will become final by April 11, following a public comment period and further evaluation by the agency.

The U.S. Food and Drug Administration had approved Aduhelm last June and later said it was appropriate for patients with mild symptoms or early-stage Alzheimer’s.

Aduhelm clears brain plaque thought to play a role in Alzheimer’s disease, and regulators made their call based on research showing the drug seemed likely to benefit patients. But they’ve asked for another study.

Biogen said last month that it would submit final plans for that study to the Food and Drug Administration in March. It then plans to have the first patient screened for the research by May.

Researchers will aim to enroll about 1,300 people with early-stage Alzheimer’s and expect to complete the research about four years after the study begins.

Aduhelm has been hailed as a promising treatment by some researchers because it has the potential to slow the fatal Alzheimer’s. No drugs on the market currently do that.

But concerns about the cost and effectiveness have slowed the drug’s debut.

Biogen CEO Michel Vounatsos said on Monday that the company now has about 220 sites treating patients with Aduhelm.

Biogen said in June, shortly after the FDA approval, that about 900 sites in the U.S. have the equipment and expertise to immediately begin giving the drug, which requires monthly IVs.

Shares of Cambridge, Massachusetts-based Biogen Inc. fell $16.18, or 6.7%, to close Wednesday at $225.34.

The stock had soared past $400 after the FDA decision in June.

___

Follow Tom Murphy on Twitter at @thpmurphy

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

Israeli Embassy...

Associated Press

US airman dies after setting himself ablaze outside Israeli Embassy in Israel-Hamas war protest

An active-duty member of the U.S. Air Force has died after he set himself ablaze outside the Israeli Embassy in Washington, D.C.

1 day ago

Biden and Trump to visit Mexico border Thursday immigration...

Associated Press

Biden and Trump both plan trips to the Mexico border Thursday, dueling for advantage on immigration

President Joe Biden and former President Donald Trump will make dueling trips to the U.S-Mexico border on Thursday.

1 day ago

Arizona and New York attorneys feud over extraditing suspect...

Associated Press

Why Alvin Bragg and Rachel Mitchell are fighting over extraditing suspect in New York hotel killing

Maricopa County Attorney Rachel Mitchell says she isn't into extraditing a suspect due to her lack of faith in Manhattan’s top prosecutor.

5 days ago

A Gila monster is displayed at the Woodland Park Zoo in Seattle, Dec. 14, 2018. A 34-year-old Color...

Associated Press

Colorado man dies after being bitten by pet Gila monster

A Colorado man has died after being bitten by his pet Gila monster in what would be a rare death by one of the desert lizards if the creature's venom turns out to have been the cause.

6 days ago

Police clear the area following a shooting at the Kansas City Chiefs NFL football Super Bowl celebr...

Associated Press

1 dead, many wounded after shooting at Kansas City Chiefs’ Super Bowl victory parade

One person died after 22 people were hit by gunfire in a shooting at the end of the Kansas Chiefs' Super Bowl victory celebration Wednesday.

13 days ago

This image from House Television shows House Speaker Mike Johnson of La., banging the gavel after h...

Associated Press

GOP-led House impeaches Homeland Security Secretary Mayorkas — by one vote — over border management

Having failed to impeach Homeland Security Secretary Alejandro Mayorkas the first time, House Republicans are determined to try again Tuesday.

14 days ago

Sponsored Articles

...

Day & Night Air Conditioning, Heating and Plumbing

Day & Night is looking for the oldest AC in the Valley

Does your air conditioner make weird noises or a burning smell when it starts? If so, you may be due for an AC unit replacement.

...

Collins Comfort Masters

Avoid a potential emergency and get your home’s heating and furnace safety checked

With the weather getting colder throughout the Valley, the best time to make sure your heating is all up to date is now. 

...

Sanderson Ford

The best ways to honor our heroes on Veterans Day and give back to the community

Veterans Day is fast approaching and there's no better way to support our veterans than to donate to the Military Assistance Mission.

Biogen tumbles after Medicare lays out Aduhelm coverage plan